Roche pulls Accutane after damage suits; Europe lifts restrictions on UCB's Neupro;

> Roche is pulling its Accutane acne medicine from the U.S. market after juries awarded at least $33 million in damages to users who blamed the drug for bowel disease, saying that the drug also faces serious generic challenges. Report

> UCB said the European Commission has lifted restrictions on its Parkinson's disease drug Neupro, and that its talks with the FDA to once again market the drug in the U.S. are ongoing. Report

> A 10th patient taking Biogen Idec's multiple sclerosis drug Tysabri has developed the potentially deadly brain infection PML, the company announced in its weekly update. Report

> Sun Pharma said it would revise its 2009-10 revenue guidance because it is not sure when U.S. subsidiary Caraco Pharmaceuticals would be able to meet the FDA's regulatory standards. Report

> Japan's Eisai inaugurated its new European headquarters in Hertfordshire, England, which will employ 500 staff working in manufacturing, research and sales. Report

> GlaxoSmithKline Capital plans to issue a six-year euro benchmark bond, IFR reported today. Report

> Watson Pharmaceuticals tapped Christopher Bodine, retired president of CVS Caremark's Healthcare Services division, to join its board of directors. Watson release

> Europe's biggest drug distributor, Celesio, acquired a majority stake in Brazil's largest drugs distributor Panpharma. Report

Biotech News

> Facing a predicted wave of new pneumonia cases triggered by a second wave of swine flu, Wyeth says it's prepared to gear up production of a new and improved vaccine for infants. The vaccine, Prevnar 13, is slated for an FDA review on September 30. Report

> Xconomy has been digging into the regulatory paperwork to find out more about Evoke Pharma, a San Diego-based developer that's been operating in stealth mode. A quarterly report from Questcor shows that Evoke licensed its experimental gastroparesis drug from the Hayward, CA company. Report

> Shares of H. Lundbeck took a hit overnight as investors digested the sour news that the FDA will need to see more data on its schizophrenia drug Serdolect before it extends an approval. That's a surprising setback. Lundbeck had been looking for an approval following an advisory panel vote largely in favor of the drug. Report

> Calling it a "generous compromise," the Obama administration says that biotech drugs should be given seven years of market exclusivity before facing competition from biosimilars. Report

> After months of wrangling, MediciNova is close to completing a deal to acquire Avigen. The two companies have reached an "understanding" that values Alameda, CA-based Avigen at its liquidation price plus $3 million. Report

And Finally... CDC officials said they received reports of nearly 6,300 new U.S. cases last week, more than in any other week since the outbreak began in late April. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.